Knowledge and attitude of dentists on bisphosphonates use in the UAE: a descriptive cross-sectional study
DOI:
https://doi.org/10.18203/2349-2902.isj20171150Keywords:
Cross-sectional studies, Dentists, Disphosphonate, Drug-related side effects and adverse reactionsAbstract
Background: The aim of this study was to assess the level of awareness and attitude of dentists practicing in the UAE about bisphosphonate intake and its dental implications.
Methods: A descriptive cross-sectional study using a 15 close-ended and fixed choice questions was performed on a representative sample of 502 dentists practicing in the UAE.
Results: The majority of the practitioners did not report treating patients on a bisphosphonate. Most of the participants were not familiar with the route of administration of the drug or the spectrum of side effects except for BRONJ which was regarded as the most common adverse effect. Furthermore, only a minority were aware of the standard treatment for patients on Bps.
Conclusions:The responses received not only highlight the lack of knowledge among practicing dentists regarding dental management of such cases but also urges the need for dissemination of guidelines for best practice in this field.
Metrics
References
Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2001;4(1):30-4.
Krueger CD, West PM, Sargent M, Lodolce AE, Pickard SA. Bisphosphonate-induced osteoporosis of the jaw. Ann Pharmacother. 2007;41(1):276-84.
British Dental Association, 2008. Bisphosphonates. Fact File. London: BDA.
Arrain Y, Masud T. Recent recommendations on bisphosphonate-associated osteochemonecrosis of the jaws. Dent Update. 2008;35(1):238-42.
Mosaferi H, Fazlyab M, Sharifi S, Rahimian S. Bisphosphonate-induced osteonecrosis of the maxilla resembling an infectious endodontic lesion. Iran Endod J. 2016;11(1):67-70.
Ruggiero SL, Dodson TB, Assael LA. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws- 2014 update. J Oral Maxillofac Surg. 2014;72(6):1-26.
Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2014;12(233):233-47.
Masson DR, O’Calloghan E, Seager M. The knowledge and attitudes of North Wales health care professionals to bisphosphonate associated osteochemonecrosis of the jaws. J Disability Oral Health. 2009;10(4):175-83.
Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of Ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg. 2015;73(6):1095-105.
Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011;32(8):830-35.
Maha A. Al-Mohaya. Hesham I. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med. 2011;32(8):830-35.
Sirmahan C, Firat S, Cengizhan K. Bisphosphonates and Bone, Orthopedic Surgery. 1st ed. Intechopen. 2012.
Russell RG. Bisphosphonates: The first 40 years. Bone. 2011;49(1):2-19.
Giger EV. Castagner B and Leroux JC. Biomedical applications of bisphosphonates. J Control Release. 2013;167(1):175-88.
Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Trans Med. 2011;11(303):1-8.
Lim V, Clarke BL. New therapeutic targets for osteoporosis: beyond denosumab. Maturitas. 2012;73(1):269-72.
Basso FG. Turrioni AP. Hebling J, de Souza CC. Effects of zoledronic acid on odontoblast-like cells. Arch Oral Biol. 2013;58(1):467-73.
Abela S, Chotai M, Bister D. What you need to know about bisphosphonates: an overview and general recommendations for orthodontic treatment. J Orthod. 2012;39(19):186-92.
Saldanha S, Shenoy VK, Eachampati P, Uppal N. Dental implications of bisphophonate-related osteonecrosis. Gerodontology Society and John Wiley and Sons A/S. Gerodontology. 2012;29(3):177-87.
Lewis DM. Clinical: Bisphosphonates, phossy jaw, and BRONJ. ODA J. 2011;102(5):36-9.
Tsao C, Darby I, Ebeling PR. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71(8):1360-6.
Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg. 2013;39(1):9-13.
Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskel Dis. 2013;5(3):107-11.
Compston J, Bilezikian J. Bisphosphonate therapy for osteoporosis: The long and short of it. J Bone Miner Res. 2013;27(2):240-2.
Downloads
Published
How to Cite
Issue
Section
